Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
DTaP protects children against diphtheria, tetanus, and pertussis (whooping cough). Given as a 5-dose series between ages 2 months and 6 years, it's one of the most frequently administered childhood vaccines — and one of the most reported in VAERS.
The following symptoms are most frequently reported after DTaP vaccination:
The original DTP vaccine used whole pertussis bacteria and was associated with higher rates of fever, fussiness, and rare neurological events. The modern DTaP uses purified (acellular) pertussis components and has a significantly improved safety profile.
When looking at VAERS data, it's important to separate pre-1997 DTP reports from modern DTaP reports. The 2,414 death reports across both formulations largely reflect the older vaccine and the era before improved infant health monitoring.
Common (up to 50% of doses):
Less common:
Rare:
DTaP is almost always given alongside other vaccines (Hib, IPV, PCV13, hepatitis B, rotavirus) at the 2, 4, and 6-month visits. This means many VAERS reports listing DTaP also list other vaccines — making it impossible to attribute symptoms to DTaP alone from VAERS data.
DTaP is given as a 5-dose series in early childhood. See exactly when each dose is due on the CDC vaccine schedule and our 2026 vaccine schedule analysis.
As of mid-2026, the DTaP vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into DTaP vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like DTaP has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for DTaP vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about DTaP vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.
As of mid-2026, the DTaP vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into DTaP vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like DTaP has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for DTaP vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about DTaP vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.